This is a monocentric cohort study, prospective and interventional with minimal risks and constraints for advanced breast cancer. The planned interventions are collection of biological samples at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib treatment with a clinical-biological database.
Patients enrolled in the study will receive the following interventions: * Biospecimen sample collection: before and during treatment, and at progression * Tumor biopsy before treatment and at progression The aim of this study is to describe molecular changes associated with resistance to Palbociclib at the individual level and describe longitudinal changes in the profile of tumor, VOCs and exosomes according to treatment response. Other objectives of the study include: * Proportion of single or shared molecular alterations / signatures between patients at progression time * Associations between tumor signatures, VOCs and exosomes * Compare molecular changes identified by proteomics with those observed by genomics / transcriptomics * Compare the evolution of VOCs and exosomes over time with evolution of liquid biopsy markers.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
25
Before and during treatment, and at progression, collection of : * Blood * Exhaled air * Saliva * Sweat * Tears * Urine
Centre Oscar Lambret
Lille, France, France
Intrapatient variation in molecular profiles at progression compared to baseline
Variation over time in the rate of VOCs in response to treatment and in progression situations.
Time frame: From date of inclusion until the date of first documented progression (around 2 years)
longitudinal changes in VOCs profile and exosomes according to response to treatment
variation over time in exosomes count in response to treatment and in progression situations
Time frame: From date of inclusion until the date of first documented progression, assessed up to 2 years
Proportion of alterations / molecular signatures unique or shared between patients at progression
Frequency of molecular alterations in the population
Time frame: At progression time, up to 2 years
Correlation between tumor signatures, VOCs and exosomes
Distribution of VOCs and exosome profiles according to the different molecular profiles of tumors that will be identified
Time frame: At progression time, up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.